Bayer
FDA approves Bayer’s Stivarga
October 1, 2012Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin
The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …
Acino plant opens to serve Bayer contraceptive patch needs
August 14, 2012Manufacturing and Production Acino, Bayer, R&D, Swiss, contraceptive
Acino has officially opened its new manufacturing facility for transdermal patch products in Miesbach, Germany, which it says makes it …
Bayer raises guidance after strong sales
July 31, 2012Sales and Marketing Bayer, Nexavar, Q2, Xarelto, Yasmin
The Bayer Group has raised its full-year guidance for 2012 following positive results in the second quarter. This is despite …
Bayer guilty of multiple Code breaches
July 30, 2012Medical Communications, Sales and Marketing ABPI Code, Bayer, Xarelto, breach, clause
Bayer Healthcare has admitted to 12 breaches of the ABPI Code after one of its staff developed and distributed drug …
NICE yes for Xarelto to treat blood clots
July 25, 2012Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto
NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …
Priority review for Xarelto’s new indications
July 10, 2012Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Eliquis, FDA, Janssen, Pradaxa, Xarelto
Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …
FDA rejects licence extension for Xarelto
June 26, 2012Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto
The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …
AstraZeneca buys Ardea Biosciences
June 22, 2012Research and Development, Sales and Marketing Abbott, Ardea Biosciences, AstraZeneca, Bayer, Humira, Takeda
AstraZeneca has completed its acquisition of US firm Ardea Biosciences in a $1.26 billion deal that it hopes will shore …
ABPI: we don’t have the answers for digital yet
June 14, 2012Medical Communications, Sales and Marketing ABPI, Bayer, Deepak Khanna, Shire, digital, online
Pharma’s use of digital media is posing questions that can’t yet be answered, says the new ABPI president Deepak Khanna. …
Sanofi submits key MS pill for approval
June 12, 2012Research and Development, Sales and Marketing Bayer, EMA, FDA, Genzyme, Lemtrada, MS, Sanofi
Sanofi has submitted its multiple sclerosis pill Lemtrada for regulatory reviews in the US and Europe. Lemtrada (alemtuzumab), originally developed …
UK Prix Galien shortlist announced
May 30, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing Bayer, Janssen, Xarelto, awards, prix galien
The UK award for the most innovative new drug has been moved a step closer with the release of a …
NICE recommends Xarelto for stroke prevention
May 23, 2012Sales and Marketing Bayer, DVT, NICE, Pradaxa, Xarelto, anticoagulant
NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients. The watchdog’s final …
Torisel fails in head-to-head study with Nexavar
May 16, 2012Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc
Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial. The Phase III study was …
Algeta to co-promote Alpharadin in US
April 12, 2012Sales and Marketing Algeta, Bayer, prostate cancer
Algeta has exercised its option to co-promote Alpharadin for the treatment of cancer patients with bone metastases in the United …
Bayer cancer drug meets Phase III goal
April 3, 2012Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib
Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
